Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
a technology for osteoarticular diseases and pharmaceutical compositions, applied in the field of pharmaceutical compositions, can solve the problems of pain and stiffness pain at rest or pain with limited motion, and swelling of the affected joints, and achieves superior or at least equivalent effect, shortening the onset of action, and prolonging the effect of action
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
[0069]Four patients suffering from gonarthritis with knee effusion were administered one intra-articular injection of about 20 mg of hyaluronic acid and about 150 μg of clonidine in the injured knee. A second and a third intra-articular injections were realized 7 and 14 days later. Before each injection, the intra-articular liquid was removed and measured. Pain and mobility were evaluated at baseline (day 0), 48-72 hours after the intra-articular injections, before the next injection (day 7 and day 14) and at day 21. The evaluations consisted in a 0-100 mm visual analogue scale filled in by the patient recording pain intensity (0=no pain, 100=intolerable pain), the WOMAC score (worse possible score=96) recording pain and mobility and an algofunctional scale (Lequesne Index, worse score=24).
[0070]As shown in FIGS. 1, 2 and 3, the intra-articular administration of the combination induced unexpectedly an relief in pain (decrease in VAS from 86.5 mm to 14.5 mm) in 48 hours and the 2 re-...
example 2
[0071]To Two Patients Suffering from coxarthritis, was administered a single intra-articular injection of about 20 mg of hyaluronic acid and about 150 μg of clonidine in the injured hip. Pain and mobility were evaluated at baseline (day 0), and at day 7, day 14, day 21 and day 28. The evaluations consisted in a 0-100 mm visual analog scale filled in by the patient recording pain intensity (0=no pain, 100=intolerable pain), the WOMAC score (worse possible score=96) recording pain and mobility and an algofunctional scale (Lequesne, worse score=24).
[0072]In patients with coxarthritis who were treated with this combination, the effect of a single intra-articular injection of about 20 mg of hyaluronic acid and about 150 μg of clonidine induced a immediate, marked, and prolonged effect as shown in FIGS. 4, 5, and 6. VAS decreased from 52 mm at baseline to 10, 11, 42 and 51 at days 7, 14, 21 and 28. Likewise, the WOMAC score decreased from 69 at baseline to 27, 28, 43 and 72 at days 7, 14,...
example 3
[0077]Clinical Experience with Intra-articular Products. The most comprehensive clinical data have been reported for intra-articular (i) corticosteroids, (ii) hyaluronic acid and (iii) TNFα inhibitors.
[0078]In a recent paper, Uthman et al. (Postgrad Med J. 2003 August; 79(934):449-53) reviewed all published data with intra-articular products. Besides corticosteroids and hyaluronic acid, only anecdotic reports have been published on substances or approaches as diverse as orgotein, radiation synovectomy, dextrose prolotherapy, silicone, saline lavage, saline injection without lavage, analgesic agents, glucosamine, somatostatin, sodium pentosan polysulfate, chloroquine, mucopolysaccharide polysulfuric acid ester, lactic acid solution, and thiotepa cytostatica, without conclusive evidence of efficacy.
PUM
| Property | Measurement | Unit |
|---|---|---|
| body weight | aaaaa | aaaaa |
| average molecular weight | aaaaa | aaaaa |
| molecular mass | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More